Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Predict4Health
The study aims to demonstrate improvement of the prevalence of biopsies leading to therapeutic change in the Predigraft group compared to the Standard of care group in kidney transplanted patients.
It is hypothesized that using Predigraft as a monitoring tool will help the physician detect earlier and more often abnormalities with the patient allograft. This should lead to an increased number of biopsies leading to therapeutic change. These biopsies should be performed earlier than without the iBox monitoring tool. This would improve long-term allograft function, kidney allograft and patient survival.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women, age ≥ 18 years old at the time of consent.
Patients receiving a living or deceased donor kidney allograft.
Patients transplanted at least 3 months before inclusion.
Patients who signed the informed consent form and are willing to comply with study procedures.
